evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

169 questions · 174 findings · 18 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 53 · 30.5%GRADE not reported 13 · 7.5%Very low 23 · 13.2%Low 41 · 23.6%Moderate 34 · 19.5%High 10 · 5.7%

Low dose isotretinoin 0.3 mg/kg vs doxycycline

Participant‐assessed improvement in rosacea severity · Participants with rosacea

Low dose isotretinoin 0.3 mg/kg leads to higher participant‐assessed improvement in rosacea severity1 Good to… compared with doxycycline 50‐100 mg (high certainty).

1 finding from 1 review

Low dose isotretinoin 0.3 mg/kg vs doxycycline

Proportion of participants with adverse event · Participants with rosacea

Low dose isotretinoin 0.3 mg/kg showed no clear difference in proportion of participants with adverse event compared with doxycycline 50‐100 mg (high certainty).

1 finding from 1 review

Low dose isotretinoin 0.3 mg/kg vs doxycycline

Physician‐assessed improvement in rosacea severity · Participants with rosacea

Low dose isotretinoin 0.3 mg/kg leads to higher physician‐assessed improvement in rosacea severity1 Complete… compared with doxycycline 50‐100 mg (high certainty).

1 finding from 1 review

Low dose isotretinoin 0.3 mg/kg vs doxycycline

Assessment of erythema or telangiectasia Improved or healed · Participants with rosacea

Low dose isotretinoin 0.3 mg/kg showed no clear difference in assessment of erythema or telangiectasia Improved or healed compared with doxycycline 50‐100 mg (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Adverse effects: headache · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).

1 finding from 1 review